1st Quarter - Report

RARE DISEASE COMPANY COALITION for RARE DISEASE COMPANY COALITION

Firm
Client
Income
—
Expenses
$110,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals

LobbyistCovered position, as disclosed
STACEY FRISK —
YOKO ROSENBAUM —
GABBI SALMON New Legislative Intern, Sen. Lamar Alexander.

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 1262 (119th), H.R. 1762 (119th)

Trade (domestic/foreign) TRD

Proclamation 11020 - Section 232 Pharmaceutical Tariffs

LobbyistCovered position, as disclosed
STACEY FRISK —
GABBI SALMON New Legislative Intern, Sen. Lamar Alexander.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.